Posted by Michael Wonder on 04 Jun 2018
FDA chief expects agency to play role in overseeing requests for unproven drugs
3 June 2018 - Scott Gottlieb reacts to new ‘Right to Try’ law aimed at weakening FDA’s power in such cases.
U.S. Food and Drug Administration Commissioner Scott Gottlieb said he expects the agency will still decide in some cases whether terminally ill patients can receive unproven drugs, despite a new law intended to weaken the FDA’s power over such cases.
The new “Right to Try” law, signed by President Donald Trump last week, allows terminally ill patients to try experimental drugs outside of standard clinical trials, without needing FDA approval and as long as drug companies are willing to provide them.
